Melatonin targeting non-coding RNAs in cancer: Focus on mechanisms and potential therapeutic targets.

Alireza Mafi, Atoosa Keshavarzmotamed, Neda Hedayati, Zahra Yeganeh Boroujeni, Russel J Reiter, Rohollah Mousavi Dehmordi, Mohammad Hossein Aarabi, Malihe Rezaee, Zatollah Asemi

Journal: European journal of pharmacology 2023;950():175755

PMID: 37119959

Full Text on Elsevier Science View on PubMed

Abstract

Despite, melatonin is mainly known as a regulatory factor for circadian rhythm, its notable role in other fundamental biological processes, such as redox homeostasis and programmed cell death, has been found. In this line, a growing body of evidence indicated that melatonin could apply an inhibitory effect on the tumorigenic processes. Hence, melatonin might be considered an efficient adjuvant agent for cancer treatment. Besides, the physiological and pathological functions of non-coding RNAs (ncRNAs) in various disease, particularly cancers, have been expanded over the past two decades. It is well-established that ncRNAs can modulate the gene expression at various levels. Thereby, ncRNAs can regulate the numerous biological processes, including cell proliferation, cell metabolism, apoptosis, and cell cycle. Recently, targeting the ncRNAs expression provides a novel insight in the therapeutic approaches for cancer treatment. Moreover, accumulating investigations have revealed that melatonin could impact the expression of different ncRNAs in a multiple disorders, including cancer. Therefore, in the precent study, we discuss the potential roles of melatonin in modulating the expression of ncRNAs and the related molecular pathways in different types of cancer. Also, we highlighted its importance in therapeutic application and translational medicine in cancer treatment.

Address: Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran; Nutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: [email protected].; Student Research Committee, Guilan University of Medical Sciences, Rasht, Iran. Electronic address: [email protected].; School of Medicine, Iran University of Medical Science, Tehran, Iran. Electronic address: [email protected].; School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: [email protected].; Department of Cell Systems and Anatomy, UT Health. Long School of Medicine, San Antonio, TX, USA. Electronic address: [email protected].; Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: [email protected].; Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: [email protected].; Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: [email protected].; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: [email protected].

DOI: 10.1016/j.ejphar.2023.175755

Link outs

Free resources

Medical:

https://medlineplus.gov/cancer.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-68

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Melatonin, RNA, Untranslated, Neoplasms, Cell Cycle